NewAmsterdam Pharma (NAMS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $19.83, -3.83% vs the prior close of $20.62.
- Volume 1.94M shares, 1.3x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
NAMS slides 3.8% to $19.83, a 52-week low. Closed at $19.83, -3.83% vs the prior close of $20.62. Day range $19.71–$20.67, opened at $20.51.
NAMS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — NAMS slides 3.8% to $19.83, a 52-week low
- Closed at $19.83, -3.83% vs the prior close of $20.62. Day range $19.71–$20.67, opened at $20.51.
- Volume was 1.94M shares, 1.3x its 50-day average of 1.48M.
- Price is -18.2% vs its 50-day average ($24.24) and -34.9% vs its 200-day average ($30.47).
- 52-week range $19.58–$42.21; today's close sits at 1% of that range, 53.0% below the 52-week high.
Oct 15, 2026 — NAMS jumps 3.0% to $20.62
- Closed at $20.62, +3.05% vs the prior close of $20.01. Day range $20.21–$21.12, opened at $20.30.
- Volume was 881.90K shares, 0.6x its 50-day average of 1.50M — lighter than usual.
- Price is -15.5% vs its 50-day average ($24.39) and -32.5% vs its 200-day average ($30.54).
- 52-week range $19.58–$42.21; today's close sits at 5% of that range, 51.1% below the 52-week high.
Oct 14, 2026 — NAMS dips 0.9% to $20.01, a 52-week low, 3 down days in a row
- Closed at $20.01, -0.89% vs the prior close of $20.19. Day range $19.58–$20.75, opened at $20.08.
- Volume was 2.19M shares, 1.5x its 50-day average of 1.48M.
- Price is -18.4% vs its 50-day average ($24.53) and -34.6% vs its 200-day average ($30.61).
- 52-week range $19.58–$42.21; today's close sits at 2% of that range, 52.6% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — NAMS slides 5.0% to $20.19, a 52-week low
- Closed at $20.19, -4.99% vs the prior close of $21.25. Day range $20.04–$21.33, opened at $21.20.
- Volume was 989.30K shares, 0.7x its 50-day average of 1.48M.
- Price is -18.2% vs its 50-day average ($24.68) and -34.2% vs its 200-day average ($30.69).
- 52-week range $20.04–$42.21; today's close sits at 1% of that range, 52.2% below the 52-week high.
Oct 12, 2026 — NAMS dips 1.5% to $21.25
- Closed at $21.25, -1.51% vs the prior close of $21.58. Day range $21.04–$21.97, opened at $21.28.
- Volume was 812.30K shares, 0.5x its 50-day average of 1.48M — lighter than usual.
- Price is -14.4% vs its 50-day average ($24.83) and -30.9% vs its 200-day average ($30.77).
- 52-week range $20.91–$42.21; today's close sits at 2% of that range, 49.7% below the 52-week high.
Oct 9, 2026 — NAMS rises 1.5% to $21.58
- Closed at $21.58, +1.48% vs the prior close of $21.26. Day range $21.02–$21.79, opened at $21.25.
- Volume was 1.27M shares, 0.9x its 50-day average of 1.47M.
- Price is -13.6% vs its 50-day average ($24.96) and -30.0% vs its 200-day average ($30.84).
- 52-week range $20.91–$42.21; today's close sits at 3% of that range, 48.9% below the 52-week high.
Oct 8, 2026 — NAMS slides 3.9% to $21.26, 6 down days in a row
- Closed at $21.26, -3.93% vs the prior close of $22.13. Day range $20.91–$22.13, opened at $22.00.
- Volume was 1.67M shares, 1.1x its 50-day average of 1.46M.
- Price is -15.3% vs its 50-day average ($25.10) and -31.2% vs its 200-day average ($30.92).
- 52-week range $20.91–$42.21; today's close sits at 2% of that range, 49.6% below the 52-week high.
- That makes 6 straight losses.
Oct 7, 2026 — NAMS dips 0.6% to $22.13, 5 down days in a row
- Closed at $22.13, -0.63% vs the prior close of $22.27. Day range $21.85–$22.72, opened at $22.07.
- Volume was 1.38M shares, 1.0x its 50-day average of 1.45M.
- Price is -12.3% vs its 50-day average ($25.23) and -28.6% vs its 200-day average ($30.99).
- 52-week range $21.02–$42.21; today's close sits at 5% of that range, 47.6% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — NAMS dips 2.3% to $22.27, 4 down days in a row
- Closed at $22.27, -2.32% vs the prior close of $22.80. Day range $21.44–$23.11, opened at $23.06.
- Volume was 1.27M shares, 0.9x its 50-day average of 1.44M.
- Price is -12.1% vs its 50-day average ($25.35) and -28.3% vs its 200-day average ($31.04).
- 52-week range $21.02–$42.21; today's close sits at 6% of that range, 47.2% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — NAMS dips 1.7% to $22.80, 3 down days in a row
- Closed at $22.80, -1.72% vs the prior close of $23.20. Day range $22.23–$23.34, opened at $22.84.
- Volume was 1.18M shares, 0.8x its 50-day average of 1.44M.
- Price is -10.6% vs its 50-day average ($25.50) and -26.7% vs its 200-day average ($31.10).
- 52-week range $21.02–$42.21; today's close sits at 8% of that range, 46.0% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — NAMS slides 4.0% to $23.20
- Closed at $23.20, -3.97% vs the prior close of $24.16. Day range $22.67–$24.75, opened at $24.60.
- Volume was 1.55M shares, 1.1x its 50-day average of 1.43M.
- Price is -9.5% vs its 50-day average ($25.64) and -25.5% vs its 200-day average ($31.16).
- 52-week range $21.02–$42.21; today's close sits at 10% of that range, 45.0% below the 52-week high.
NAMS latest news & SEC filings
Every SEC filing by or about NAMS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kastelein Johannes Jacob Pieter converted options/RSUs into 50,246 shares on Sep 30, 2026; now holds 119,548
- Kastelein Johannes Jacob Pieter sold 50,246 shares at $25.03 (≈$1.26M) on Sep 30, 2026; now holds 69,302
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 22, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Davidson Michael H. bought 10,000 shares at $22.65 (≈$226.50K) on Sep 14, 2026
- Davidson Michael H. bought 10,000 shares at $22.65 (≈$226.50K) on Sep 14, 2026
- Davidson Michael H. bought 10,000 shares at $22.65 (≈$226.50K) on Sep 14, 2026
- Davidson Michael H. bought 10,000 shares at $22.65 (≈$226.50K) on Sep 14, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Smither John W sold 1,600 shares at $25.32 (≈$40.51K) on Sep 4, 2026
- Smither John W sold 1,600 shares at $25.32 (≈$40.51K) on Sep 4, 2026
- Smither John W sold 1,600 shares at $25.32 (≈$40.51K) on Sep 4, 2026
- Smither John W sold 1,600 shares at $25.32 (≈$40.51K) on Sep 4, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kastelein Johannes Jacob Pieter sold 125,000 shares at $26.91 (≈$3.36M) on Aug 24, 2026
- Kastelein Johannes Jacob Pieter sold 125,000 shares at $26.91 (≈$3.36M) on Aug 24, 2026
- Kastelein Johannes Jacob Pieter sold 125,000 shares at $26.91 (≈$3.36M) on Aug 24, 2026
- Kastelein Johannes Jacob Pieter sold 125,000 shares at $26.91 (≈$3.36M) on Aug 24, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 24, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form 8-K/A — Current report (amended)
Amended current report
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 6, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $3.70M (prior year $19.14M) (-80.7% vs Jun 30, 2025)
- Net income: -$64.14M (prior year -$17.36M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.52 (prior year -$0.15) (loss widened vs Jun 30, 2025)
Things to know before you trade NAMS
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 18, 2026, Jan 9, 2026. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.20% (largest 5.0%).
- Liquidity: about 1.69M shares (≈$33.48M) trade per day on average.
- 52-week position: $19.83 vs a range of $19.58–$42.21 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 21 sales; latest: Michael H. Davidson bought 10,000 shares on Sep 14, 2026.
- Latest filings: 8-K Sep 29, 2026; 8-K Sep 21, 2026; 8-K Aug 14, 2026.
- Share count: 119.54M shares outstanding (Aug 3, 2026), +6.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
NAMS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 20.51 | 20.67 | 19.71 | 19.83 | 1.94M |
| Oct 15, 2026 | 20.30 | 21.12 | 20.21 | 20.62 | 881.90K |
| Oct 14, 2026 | 20.08 | 20.75 | 19.58 | 20.01 | 2.19M |
| Oct 13, 2026 | 21.20 | 21.33 | 20.04 | 20.19 | 989.30K |
| Oct 12, 2026 | 21.28 | 21.97 | 21.04 | 21.25 | 812.30K |
| Oct 9, 2026 | 21.25 | 21.79 | 21.02 | 21.58 | 1.27M |
| Oct 8, 2026 | 22.00 | 22.13 | 20.91 | 21.26 | 1.67M |
| Oct 7, 2026 | 22.07 | 22.72 | 21.85 | 22.13 | 1.38M |
| Oct 6, 2026 | 23.06 | 23.11 | 21.44 | 22.27 | 1.27M |
| Oct 5, 2026 | 22.84 | 23.34 | 22.23 | 22.80 | 1.18M |
| Oct 2, 2026 | 24.60 | 24.75 | 22.67 | 23.20 | 1.55M |
| Oct 1, 2026 | 24.23 | 24.83 | 24.06 | 24.16 | 1.63M |
| Sep 30, 2026 | 24.00 | 25.12 | 23.96 | 24.32 | 2.27M |
| Sep 29, 2026 | 23.52 | 24.54 | 23.26 | 23.81 | 1.07M |
| Sep 28, 2026 | 22.50 | 24.21 | 22.25 | 23.58 | 2.06M |
| Sep 25, 2026 | 22.93 | 22.96 | 22.35 | 22.58 | 1.14M |
| Sep 24, 2026 | 22.47 | 23.19 | 21.95 | 22.74 | 1.82M |
| Sep 23, 2026 | 23.31 | 23.32 | 22.08 | 22.68 | 2.27M |
| Sep 22, 2026 | 22.91 | 23.73 | 22.13 | 23.32 | 2.87M |
| Sep 21, 2026 | 22.95 | 23.20 | 21.68 | 22.58 | 3.53M |
About NewAmsterdam Pharma
NewAmsterdam Pharma (NAMS) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NARRDEN, Netherlands. State of incorporation: Netherlands. Fiscal year ends December 31. SEC CIK 1936258.
NAMS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Michael H. Davidson | Chief Executive Officer | Sep 15, 2026 |
| Adele M. Gulfo | Director | Jan 9, 2026 |
| Johannes Jacob Pieter Kastelein | Chief Scientific Officer | Aug 25, 2026 |
| Louis G Lange | Director | Mar 12, 2026 |
| William Lewis | Director | Jan 9, 2026 |
| Mark C. Mckenna | Director | Jan 9, 2026 |
| John W Smither | Director | Sep 9, 2026 |
| Der Kamp Hilde Johanna Van | Director | Jan 9, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Michael H. Davidson | Chief Executive Officer | Sep 15, 2026 |
| Robert William Gunning | Vice President, Controller | Sep 3, 2026 |
| Johannes Jacob Pieter Kastelein | Chief Scientific Officer | Aug 25, 2026 |
| Louise Frederika Kooij | Chief Accounting Officer | Jul 22, 2026 |
| Mayur Ian Somaiya | Chief Financial Officer | Jan 22, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 14, 2026 | Michael H. Davidson | Buy | 10,000 | $22.65 |
| Sep 14, 2026 | Michael H. Davidson | Buy | 10,000 | $22.65 |
| Sep 14, 2026 | Michael H. Davidson | Buy | 10,000 | $22.65 |
| Sep 14, 2026 | Michael H. Davidson | Buy | 10,000 | $22.65 |
| Sep 4, 2026 | John W Smither | Sale | 1,600 | $25.32 |
| Sep 4, 2026 | John W Smither | Sale | 1,600 | $25.32 |
| Sep 4, 2026 | John W Smither | Sale | 1,600 | $25.32 |
| Sep 4, 2026 | John W Smither | Sale | 1,600 | $25.32 |
| Aug 24, 2026 | Johannes Jacob Pieter Kastelein | Sale | 125,000 | $26.91 |
| Aug 24, 2026 | Johannes Jacob Pieter Kastelein | Sale | 125,000 | $26.91 |
| Aug 24, 2026 | Johannes Jacob Pieter Kastelein | Sale | 125,000 | $26.91 |
| Aug 24, 2026 | Johannes Jacob Pieter Kastelein | Sale | 125,000 | $26.91 |
| Jul 20, 2026 | Louise Frederika Kooij | Sale | 2,915 | $31.71 |
| Jul 20, 2026 | Louise Frederika Kooij | Sale | 31,885 | $31.05 |
| Jul 20, 2026 | Louise Frederika Kooij | Sale | 70,200 | $29.96 |
NAMS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $22.50M | $-203.82M | -1.72 | $-147.78M |
| Dec 31, 2024 | $45.56M | $-241.60M | -2.56 | $-158.56M |
| Dec 31, 2023 | $14.09M | $-176.94M | -2.15 | $-141.22M |
| Dec 31, 2022 | $102.69M | $-22.63M | -1.19 | $10.66M |
| Dec 31, 2021 | — | $-41.78M | -3.81 | $-29.51M |
Latest balance sheet: total assets $704.45M, total liabilities $73.03M, cash $424.15M (as of Jun 30, 2026).
NAMS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $27.42 |
| May 7, 2026 | 8-K Item 2.02 (results) | $34.85 |
| Feb 18, 2026 | 8-K Item 2.02 (results) | $35.76 |
| Jan 9, 2026 | 8-K Item 2.02 (results) | $34.37 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $38.12 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $23.62 |
| May 8, 2025 | 8-K Item 2.02 (results) | $19.27 |
| Feb 26, 2025 | 8-K Item 2.02 (results) | $19.71 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $21.78 |
| Aug 7, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Feb 28, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on NAMS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.